The best-characterized PPARγ agonists are thiazolidinediones (TZDs), including pioglitazone and rosiglitazone, which have insulin sensitizing activity and are currently used for the treatment of type 2 diabetes (Actos and Avandia, respectively) [44]. Here, PPARG is linked to type 2 diabetes mellitus.